Key result
The combined elevation of ST2 and CRP predicted worsened outcomes and increased the risk of all-cause mortality in patients with chronic heart failure.
Why the study?
ST2 has emerged as a marker of inflammation, fibrosis, and cardiac stress, but its prognostic value combined with CRP in chronic heart failure compared to classical markers was unclear.
Does the combination of ST2 and CRP predict mortality better than individual markers in patients with chronic heart failure?
Cohort (n=178)
No
Does the combination of ST2 and CRP predict mortality better than individual markers in patients with chronic heart failure?
The combined measurement of ST2 and CRP identifies a high-risk subgroup of chronic heart failure patients, providing valuable prognostic information for mortality risk.
Answers are grounded in this paper and cite their sources.
ST2-CRP combination was associated with higher mortality in chronic HF; supports larger prospective validation before clinical risk stratification use.
Natriuretic peptides (BNP and NT-proBNP) are recognized as gold-standard predictive markers in Heart Failure (HF). However, currently ST2 (member of the interleukin 1 receptor family) has emerged as marker of inflammation, fibrosis and cardiac stress. We evaluated ST2 and CRP as prognostic markers in 178 patients with chronic heart failure in comparison with other classical markers such as clinical established parameters but also biological markers: NT-proBNP, hs-cTnT alone or in combination. In multivariate analysis, subsequent addition of ST2 led to age, CRP and ST2 as the only remaining predictors of all-cause mortality (HR 1.03, HR 1.61 and HR 2.75, respectively) as well as of cardiovascular mortality (HR 1.00, HR 2.27 and HR 3.78, respectively). The combined increase of ST2 and CRP was significant for predicting worsened outcomes leading to identify a high risk subgroup that individual assessment of either marker. The same analysis was performed with ST2 in combination with Barcelona score. Overall, our findings extend previous data demonstrating that ST2 in combination with CRP as a valuable tool for identifying patients at risk of death.
No takes yet. Share an insight, caveat, or question.
Dupuy et al. (2016) conducted a cohort in Chronic heart failure (n=178). Combined elevation of ST2 and CRP vs. Low ST2 and low CRP was evaluated on All-cause mortality (HR 5.158, 95% CI 2.33-11.41, p=<0.0001). The combined elevation of ST2 and CRP predicted worsened outcomes and increased the risk of all-cause mortality in patients with chronic heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: